ArticleMedeniyet medical journal2026
Optimal Timing of Intratympanic Corticosteroid Therapy for Idiopathic Sudden Sensorineural Hearing Loss: A Mini-Review.
Article in Medeniyet medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic sudden sensorineural hearing loss (ISSNHL) is an otologic emergency. While systemic corticosteroids are first-line therapy, intratympanic corticosteroid (ITC) injection has emerged as an important modality. The optimal timing of ITC-as primary therapy, combined initial treatment, or salvage therapy-remains controversial. To critically synthesize current evidence regarding ITC efficacy at different treatment timings and provide evidence-based clinical recommendations. A structured search of PubMed, Embase, and the Cochrane Library was conducted from database inception to December 2025 using terms sudden sensorineural hearing loss, ISSNHL, sudden deafness, intratympanic injection, ITC, intratympanic dexamethasone, and intratympanic methylprednisolone. The search identified 321 records, and additional articles were found in the reference lists of key reviews, meta-analyses, and guidelines. Studies were selected using predefined criteria, prioritizing randomized controlled trials, systematic reviews, meta-analyses, clinical practice guidelines, and relevant observational studies in adults with ISSNHL. Eligible studies evaluated ITC as primary monotherapy, combined initial therapy, or salvage therapy, and reported quantitative audiometric outcomes. Exclusion criteria included non-idiopathic sudden hearing loss, pediatric populations, non-corticosteroid intratympanic therapies, animal or laboratory-only studies, case reports, conference abstracts without full text, duplicate publications, and studies without clinically interpretable hearing outcomes. After screening, 25 studies were included. Salvage ITC provides significant benefit (OR: 6.04; 95% CI: 3.26-11.2; NNT≈3) with Grade A evidence. Combined initial therapy is superior to systemic steroids alone (OR: 2.50; 95% CI: 1.95-3.21), particularly for severe hearing loss. ITC monotherapy is non-inferior to systemic steroids (PTA difference: 2.0 dB). A stratified approach based on treatment timing is recommended. Salvage ITC should be offered to all patients with incomplete recovery. Combined therapy should be considered for patients with severe hearing loss. ITC monotherapy is appropriate when systemic steroids are contraindicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.